PhaseBio Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

PhaseBio Pharmaceuticals

10/11/2021 22:03

* PhaseBio Pharmaceuticals Inc  PHAS.OQ  reported a quarterly
adjusted loss of 66 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 61 cents per share.
* Revenue was $335.00 thousand​;  analysts expected $1.07
million. 
* PhaseBio Pharmaceuticals Inc's reported EPS for the quarter
was a loss of 66 cents​.
* The mean earnings estimate of analysts had fallen by
about 10.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* PhaseBio Pharmaceuticals Inc shares had risen by 9.0% this
quarter and gained 0.9% so far this year.
* The company reported a quarterly loss of $31.92 million.
* Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $15.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 10:03 p.m.
 ​All figures in US dollars unless otherwise stated